NASDAQ: DMACDiamedica Therapeutics Inc Stock
$3.65-0.25 (-6.41%)
Updated Jun 13, 2025
DMAC Price
$3.65
Fair Value Price
$0.07
Market Cap
$156.52M
52 Week Low
$2.14
52 Week High
$6.82
P/E
-5.7x
P/B
4.61x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$26.97M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.14
Operating Cash Flow
-$23M
Beta
0.78
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
DMAC Overview
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DMAC's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
DMAC
Ranked#330 of 464
Ranked#330 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important DMAC news, forecast changes, insider trades & much more!
DMAC News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DMAC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DMAC ($3.65) is overvalued by 5,392.63% relative to our estimate of its Fair Value price of $0.07 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
DMAC ($3.65) is not significantly undervalued (5,392.63%) relative to our estimate of its Fair Value price of $0.07 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DMAC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DMAC due diligence checks available for Premium users.
Valuation
DMAC fair value
Fair Value of DMAC stock based on Discounted Cash Flow (DCF)
Price
$3.65
Fair Value
$0.07
Overvalued by
5,392.63%
DMAC ($3.65) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DMAC ($3.65) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DMAC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DMAC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.7x
Industry
-108.97x
Market
31.36x
DMAC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.61x
Industry
4.66x
DMAC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DMAC's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.7M
Profit Margin
0%
DMAC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$38.8M
Liabilities
$4.9M
Debt to equity
0.14
DMAC's short-term assets ($37.42M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DMAC's short-term assets ($37.42M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DMAC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
DMAC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.1M
Investing
$6.6M
Financing
$91.0k
DMAC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DMAC vs Biotech Stocks
Diamedica Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.